CDX2 immunoreactivity in primary and metastatic ovarian mucinous tumours

Filippo Fraggetta, Giuseppe Pelosi, Alessia Cafici, Paolo Scollo, Paolo Nuciforo, Giuseppe Viale

Research output: Contribution to journalArticle

Abstract

The caudal-related homeobox transcription factor CDX2 regulates the differentiation of intestinal epithelial cells. Recent studies have suggested that CDX-2 immunoreactivity is strictly confined to benign and malignant intestinal epithelium. In the present study, we evaluated the prevalence of CDX2 immunoreactivity in a series of benign, borderline and malignant primary ovarian mucinous neoplasms. We tested 62 mucinous tumours of the ovary, including 28 benign cystadenomas, 18 borderline tumours, 16 adenocarcinomas, 35 serous and endometrioid ovarian lesions and 10 ovarian metastases of colonic adenocarcinoma. Overall, the CDX2 prevalence in primary mucinous tumours was 79%, including 20 of 28 (71.5%) cystadenomas, 14 of 18 (77.7%) borderline tumours and 15 of 16 (93.5%) adenocarcinomas. Immunoreactivity usually correlated with intestinal differentiation of tumour cells, although wide heterogeneity in the distribution of immunolabelled cells was noted. No immunoreactivity was observed in serous lesions; whereas, 1 of 13 (7.7%) endometrioid adenocarcinomas and all of the 10 metastatic colonic adenocarcinomas were immunostained. These results indicate that CDX2 is detectable in the majority of benign, borderline and malignant ovarian mucinous tumours and, therefore, makes this marker unsuitable when distinguishing primary from metastatic ovarian mucinous adenocarcinomas. However, CDX2 immunoreactivity could be useful in the distinction between endocervical and intestinal-type mucinous tumours of the ovary, which may have clinical relevance.

Original languageEnglish
Pages (from-to)782-786
Number of pages5
JournalVirchows Archiv
Volume443
Issue number6
DOIs
Publication statusPublished - Dec 2003

Fingerprint

Adenocarcinoma
Neoplasms
Cystadenoma
Ovary
Endometrioid Carcinoma
Mucinous Adenocarcinoma
Homeobox Genes
Intestinal Mucosa
Ovarian Neoplasms
Cell Differentiation
Epithelial Cells
Neoplasm Metastasis

Keywords

  • CDX2
  • Meastases
  • Mucinous tumours
  • Ovary
  • Primary

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

CDX2 immunoreactivity in primary and metastatic ovarian mucinous tumours. / Fraggetta, Filippo; Pelosi, Giuseppe; Cafici, Alessia; Scollo, Paolo; Nuciforo, Paolo; Viale, Giuseppe.

In: Virchows Archiv, Vol. 443, No. 6, 12.2003, p. 782-786.

Research output: Contribution to journalArticle

Fraggetta, Filippo ; Pelosi, Giuseppe ; Cafici, Alessia ; Scollo, Paolo ; Nuciforo, Paolo ; Viale, Giuseppe. / CDX2 immunoreactivity in primary and metastatic ovarian mucinous tumours. In: Virchows Archiv. 2003 ; Vol. 443, No. 6. pp. 782-786.
@article{442489908b5a42faafe11310c0ee2aef,
title = "CDX2 immunoreactivity in primary and metastatic ovarian mucinous tumours",
abstract = "The caudal-related homeobox transcription factor CDX2 regulates the differentiation of intestinal epithelial cells. Recent studies have suggested that CDX-2 immunoreactivity is strictly confined to benign and malignant intestinal epithelium. In the present study, we evaluated the prevalence of CDX2 immunoreactivity in a series of benign, borderline and malignant primary ovarian mucinous neoplasms. We tested 62 mucinous tumours of the ovary, including 28 benign cystadenomas, 18 borderline tumours, 16 adenocarcinomas, 35 serous and endometrioid ovarian lesions and 10 ovarian metastases of colonic adenocarcinoma. Overall, the CDX2 prevalence in primary mucinous tumours was 79{\%}, including 20 of 28 (71.5{\%}) cystadenomas, 14 of 18 (77.7{\%}) borderline tumours and 15 of 16 (93.5{\%}) adenocarcinomas. Immunoreactivity usually correlated with intestinal differentiation of tumour cells, although wide heterogeneity in the distribution of immunolabelled cells was noted. No immunoreactivity was observed in serous lesions; whereas, 1 of 13 (7.7{\%}) endometrioid adenocarcinomas and all of the 10 metastatic colonic adenocarcinomas were immunostained. These results indicate that CDX2 is detectable in the majority of benign, borderline and malignant ovarian mucinous tumours and, therefore, makes this marker unsuitable when distinguishing primary from metastatic ovarian mucinous adenocarcinomas. However, CDX2 immunoreactivity could be useful in the distinction between endocervical and intestinal-type mucinous tumours of the ovary, which may have clinical relevance.",
keywords = "CDX2, Meastases, Mucinous tumours, Ovary, Primary",
author = "Filippo Fraggetta and Giuseppe Pelosi and Alessia Cafici and Paolo Scollo and Paolo Nuciforo and Giuseppe Viale",
year = "2003",
month = "12",
doi = "10.1007/s00428-003-0910-3",
language = "English",
volume = "443",
pages = "782--786",
journal = "Virchows Archiv - A Pathological Anatomy and Histopathology",
issn = "0945-6317",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - CDX2 immunoreactivity in primary and metastatic ovarian mucinous tumours

AU - Fraggetta, Filippo

AU - Pelosi, Giuseppe

AU - Cafici, Alessia

AU - Scollo, Paolo

AU - Nuciforo, Paolo

AU - Viale, Giuseppe

PY - 2003/12

Y1 - 2003/12

N2 - The caudal-related homeobox transcription factor CDX2 regulates the differentiation of intestinal epithelial cells. Recent studies have suggested that CDX-2 immunoreactivity is strictly confined to benign and malignant intestinal epithelium. In the present study, we evaluated the prevalence of CDX2 immunoreactivity in a series of benign, borderline and malignant primary ovarian mucinous neoplasms. We tested 62 mucinous tumours of the ovary, including 28 benign cystadenomas, 18 borderline tumours, 16 adenocarcinomas, 35 serous and endometrioid ovarian lesions and 10 ovarian metastases of colonic adenocarcinoma. Overall, the CDX2 prevalence in primary mucinous tumours was 79%, including 20 of 28 (71.5%) cystadenomas, 14 of 18 (77.7%) borderline tumours and 15 of 16 (93.5%) adenocarcinomas. Immunoreactivity usually correlated with intestinal differentiation of tumour cells, although wide heterogeneity in the distribution of immunolabelled cells was noted. No immunoreactivity was observed in serous lesions; whereas, 1 of 13 (7.7%) endometrioid adenocarcinomas and all of the 10 metastatic colonic adenocarcinomas were immunostained. These results indicate that CDX2 is detectable in the majority of benign, borderline and malignant ovarian mucinous tumours and, therefore, makes this marker unsuitable when distinguishing primary from metastatic ovarian mucinous adenocarcinomas. However, CDX2 immunoreactivity could be useful in the distinction between endocervical and intestinal-type mucinous tumours of the ovary, which may have clinical relevance.

AB - The caudal-related homeobox transcription factor CDX2 regulates the differentiation of intestinal epithelial cells. Recent studies have suggested that CDX-2 immunoreactivity is strictly confined to benign and malignant intestinal epithelium. In the present study, we evaluated the prevalence of CDX2 immunoreactivity in a series of benign, borderline and malignant primary ovarian mucinous neoplasms. We tested 62 mucinous tumours of the ovary, including 28 benign cystadenomas, 18 borderline tumours, 16 adenocarcinomas, 35 serous and endometrioid ovarian lesions and 10 ovarian metastases of colonic adenocarcinoma. Overall, the CDX2 prevalence in primary mucinous tumours was 79%, including 20 of 28 (71.5%) cystadenomas, 14 of 18 (77.7%) borderline tumours and 15 of 16 (93.5%) adenocarcinomas. Immunoreactivity usually correlated with intestinal differentiation of tumour cells, although wide heterogeneity in the distribution of immunolabelled cells was noted. No immunoreactivity was observed in serous lesions; whereas, 1 of 13 (7.7%) endometrioid adenocarcinomas and all of the 10 metastatic colonic adenocarcinomas were immunostained. These results indicate that CDX2 is detectable in the majority of benign, borderline and malignant ovarian mucinous tumours and, therefore, makes this marker unsuitable when distinguishing primary from metastatic ovarian mucinous adenocarcinomas. However, CDX2 immunoreactivity could be useful in the distinction between endocervical and intestinal-type mucinous tumours of the ovary, which may have clinical relevance.

KW - CDX2

KW - Meastases

KW - Mucinous tumours

KW - Ovary

KW - Primary

UR - http://www.scopus.com/inward/record.url?scp=0347419393&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0347419393&partnerID=8YFLogxK

U2 - 10.1007/s00428-003-0910-3

DO - 10.1007/s00428-003-0910-3

M3 - Article

C2 - 14576939

AN - SCOPUS:0347419393

VL - 443

SP - 782

EP - 786

JO - Virchows Archiv - A Pathological Anatomy and Histopathology

JF - Virchows Archiv - A Pathological Anatomy and Histopathology

SN - 0945-6317

IS - 6

ER -